ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and…
Novartis is getting ready to steal a lot of hearts with its newest drug. The FDA has approved Entresto tablets for the treatment of heart failure.
Chris Lange Owning a few top European stocks in a well-balanced portfolio makes good sense at this juncture, especially with the U.S. markets hovering near all-time highs.
A new research report from the analysts at Cowen highlights the firm's top health care picks, many of which have some huge upside potential to the posted price targets.
What are investors, and patients, supposed to think when is launching a generic version of Diovan?
Array BioPharma has announced that it had reached a definitive agreement with Novartis to regain full worldwide rights to cancer drug binimetinib.
Chris Lange Wednesday's top analyst upgrades, downgrades and initiations include American Electric Power, BP, Halliburton, Cypress Semiconductor, J.C. Penney, Schlumberger and SanDisk.
A new research report from J.P. Morgan, makes the case that the time to buy some of the top stocks in Europe is right now.
For the third consecutive year, the company spending the most on research and development (R&D) was Germany's Volkswagen.
The data is grim: cancer is increasing. Sales of these top oncology drugs are likely to increase as well.
ThinkstockBinary events are often the key element in moving a biotech or health care stock higher. Negative binary results or actions often can move shares drastically lower. We scan our 24/7 Wall…
These are the top Wall Street analyst upgrades, downgrades and initiations see on Monday, June 9, 2014. They include BioMarin, Family Dollar, Lululemon and SunTrust.
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy…
These are the top analyst upgrades, downgrades and initiations from Wall Street for Friday, May 2, 2014. They include Avanir, Avon, Broadcom, LinkedIn, Oracle and Wynn Resorts.
Mediwound offered 5 million shares in a Thursday IPO at the low end of the expected range. Akebia Therapeutics offered 5.9 million shares in its IPO at the high end of the…
Paul Ausick 
